Inclusion Criteria:
* Healthy volunteers Age ≥18 and \<85
* Able to understand and comply with planned study procedures and sign an informed consent before performance of any study-related screening procedures
* Who has received a primary series of vaccination and ≥ 1 booster(s) of COVID-19 mRNA vaccination(s) with the last boost at least 6 months prior to the inclusion in the study
* Subjects has adequate organ functions, evidenced by normal ALT, AST, and alkaline phosphatase
* Normal haematology lab values
* Negative virology assessment
* Normal Urine testing
* Volunteers must meet the eligibility criteria in the approved package labelling of the active comparator
* For women of childbearing potential: use of an effective contraceptive method and negative pregnancy test. For male participants, use of an effective method of contraception with their partner
Exclusion Criteria:
* Acute febrile infection within the previous 72 hours and/or presenting symptoms suggestive of COVID-19 or SARS CoV 2 infection within the previous 28 days
* Immunosuppressive medications received within last three months before first IMP administration or within 6 months for chemotherapies
* Immunoglobulins within 90 days before first IMP administration
* Blood products within 120 days before first IMP administration
* Any medical condition, such as cancer, that might impair the immune response
* Use of any experimental therapy
* Intent to participate in another study of an investigational research agent within 4 weeks prior to the enrolment visit or until the end of the study
* Currently pregnant or breastfeeding
* History of severe adverse events following vaccine administration
* Any bleeding disorder considered as a contraindication to an intramuscular injection
* A condition that requires active medical intervention or monitoring to avert grave danger to Asthma other than mild, well-controlled asthma.
* Hypertension
* BMI ≥ 40 kg/m2; ≤ 18 kg/m2; or BMI ≥ 35 kg/m2 with 2 or more of the following: age \> 45, current smoker, known hyperlipidemia, blood pressure is defined as consistently ≥ 140 mm Hg systolic and ≥ 90 mm Hg diastolic
* Malignancy
* Asplenia
* Seizure disorder
* History of hereditary angioedema acquired angioedema, or idiopathic angioedema
* History of myocarditis, pericarditis, cardiomyopathy, congestive heart failure with permanent sequelae, clinically significant arrhythmia (including arrhythmia requiring medication, treatment, or clinical follow-up
* History of autoimmune disease
* Any medical, occupational, or other condition that, in the judgment of the investigator, would interfere with or serve as a contraindication to protocol adherence
* Psychiatric condition that precludes compliance with the protocol.
* Live attenuated vaccines received within 30 days before first IMP administration or scheduled within 28 days after one of the last injection according to the protocol
* Vaccines that are not live attenuated vaccines and were received within 21 days prior to first IMP administration
* Allergy treatment with antigen injections within 30 days before first IMP administration and until the end of the study
